Cannabidiol shows promise for obesity and metabolic syndrome
September 29, 2025 / CBD obesity treatment / metabolic syndrome CBD / cannabidiol appetite regulation / CBD glucose metabolism / endocannabinoid system obesity
CBD shows preclinical promise for managing obesity and metabolic syndrome by improving glucose and lipid metabolism, reducing inflammation, and moderating appetite. Human evidence remains limited and inconsistent, highlighting the need for standardized, well-controlled clinical trials.
Phenotyping obesity through a two-dimensional tree structure reveals cardiometabolic heterogeneity
September 25, 2025 / obesity phenotyping tool / cardiometabolic risk stratification / DDRTree obesity analysis / precision obesity medicine / Chinese cohort study
Using DDRTree analysis of over 18,000 individuals, researchers identified five distinct obesity phenotypes with varying cardiometabolic risks. These findings support personalized obesity management and led to the development of an online tool for risk assessment.
Inside UC Davis Health’s new approach to obesity care
September 26, 2025 / UC Davis obesity clinic / GLP-1 weight loss / personalized obesity care / non-surgical obesity treatment / multidisciplinary obesity management
UC Davis Health is launching a multidisciplinary Obesity Clinic that combines GLP-1 agonists, behavioral therapy, nutrition, physical therapy, and sleep medicine to deliver personalized, non-surgical obesity care, aiming for sustainable outcomes and improved patient quality of life.
UCP3 gene variants and obesity in a Pakistani sample population
September 26, 2025 / UCP3 gene obesity / Pakistani genetic study / obesity gene variants / South Asian genomics / population-specific obesity risk
A study in Karachi identified specific UCP3 gene variants associated with obesity in a Pakistani population. Several unique and novel variants were found exclusively in individuals with obesity, highlighting the importance of population-specific genetic research in obesity risk.
Oral GLP-1 drug promotes substantial weight loss in trial
September 23, 2024 / oral GLP-1 weight loss / orforglipron obesity trial / ATTAIN-1 study results / non-injectable GLP-1 drug / cardiometabolic risk reduction
The ATTAIN-1 Phase III trial found that orforglipron, an oral GLP-1 receptor agonist, significantly reduced weight and improved cardiometabolic markers in patients with obesity, offering a scalable, non-injectable alternative to current GLP-1 therapies.
‘Switching off’ enzyme prevents diet-induced obesity, other metabolic diseases
September 24, 2025 / CaMKK2 obesity therapy / macrophage inflammation control / metabolic disease prevention / diet-induced obesity research / immune-metabolic regulation
Researchers found that disabling the enzyme CaMKK2 in macrophages protects mice from diet-induced obesity, diabetes, and fatty liver disease by reducing inflammation and improving metabolic function—highlighting CaMKK2 as a potential therapeutic target for metabolic disorders.
New Study Finds Bariatric Surgery Associated with Greater Benefits Than GLP-1RAs Alone
September 26, 2025 / bariatric surgery benefits / GLP-1 vs surgery / obesity diabetes treatment / metabolic surgery outcomes / long-term diabetes control
A Cleveland Clinic study found bariatric surgery provides greater long-term benefits than GLP-1 receptor agonists in patients with obesity and type 2 diabetes, including improved weight loss, glycemic control, and reduced risks of cardiovascular, kidney, and eye complications.
The Biggest Loser and the Science of Metabolic Adaptation
September 24, 2025 / obesity metabolic adaptation / weight regain science / chronic disease obesity / Biggest Loser weight loss / obesity stigma medicine
Obesity is a complex, chronic disease driven by metabolic, genetic, hormonal, and psychological factors—not willpower. Studies of The Biggest Loser revealed long-term metabolic adaptation, highlighting the challenges of sustained weight loss and the need for compassionate, science-based obesity care.
LSU Health Shreveport awarded grant from National Science Foundation to research metabolic diseases
September 29, 2025 / metabolic disease research / LSU Health NSF grant / obesity diabetes liver / molecular biology training / Louisiana health innovation
LSU Health Shreveport received a $7.5M NSF grant to establish a research center focused on metabolic diseases like obesity, diabetes, and liver disease. The center will train students in biotechnology and molecular biology to develop future treatments.
Gut probiotic Christensenella tenuis reduces endotoxemia and improves metabolism in obese mice
September 26, 2024 / Christensenella tenuis probiotic / obesity endotoxemia treatment / bile acid metabolism / LPS gut barrier / metabolic disease probiotic
Christensenella tenuis improves glucose and lipid metabolism in obese mice by reducing endotoxemia through bile acid modulation and inhibition of LPS translocation. The probiotic forms bile acid–LPS complexes, preventing inflammation and offering potential for metabolic disease therapies.
Tirzepatide’s Impact on Weight with and without Diabetes
September 27, 2025 / tirzepatide weight loss / dual incretin therapy / obesity diabetes treatment / GIP GLP-1 agonist / metabolic medicine innovation
A meta-analysis shows tirzepatide, a dual GIP/GLP-1 receptor agonist, produces substantial weight loss in patients with and without diabetes while improving glycemic control in diabetics. Its dual incretin action offers broad anti-obesity potential with a tolerable safety profile.
Precision probiotics lower blood sugar and cholesterol in mice
September 28, 2025 / precision probiotics / blood glucose control / metabolic health / gut microbiota therapy / cholesterol reduction
A precision probiotic cocktail significantly reduced blood glucose, insulin, cholesterol, and body fat in mice fed a high-fat diet, suggesting targeted gut microbiota modulation may offer therapeutic benefits for hyperglycemia and metabolic syndrome.
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
September 26, 2025 / Revita therapy / post-GLP-1 weight / obesity treatment / endoscopic weight loss / duodenal resurfacing
Fractyl’s Revita® procedure helped maintain and further weight loss in patients after stopping tirzepatide, showing significant results at 3 months versus sham. This suggests Revita may address the critical gap in post-GLP-1 obesity care.
Aphaia Pharma Publishes Phase 1 and 2 Clinical Data of Oral Formulation in Patients with Obesity and Prediabetes
September 23, 2025 / oral obesity treatment / glucose tolerance improvement / gut hormone therapy / non-incretin formulation / metabolic disease innovation
Aphaia Pharma’s oral glucose formulation showed improved glucose tolerance and enteric hormone release in Phase 1 and 2 trials, offering a safe, non-incretin approach to treating prediabetes and obesity through gut-targeted metabolic modulation.
Chinese scientists identify neural basis for energy expenditure in arcuate hypothalamus
September 23, 2025 / hypothalamic neurons / energy expenditure control / obesity research / neural metabolism regulation / Crabp1 discovery
Chinese researchers identified a novel Crabp1-expressing neuron population in the arcuate hypothalamus that regulates energy expenditure, linking neural activity to thermogenesis, locomotion, and obesity—offering a new target for metabolic disease intervention beyond traditional appetite suppression.
Researchers test new drug combining five pathways to fight obesity and diabetes.
September 26, 2025 / quintuple agonist drug / obesity treatment innovation / diabetes therapy research / GLP-1 GIP PPAR / multi-pathway metabolism
A new quintuple agonist drug combining GLP-1, GIP, and PPAR activation shows superior weight loss and glucose control in animal models, offering a promising multi-pathway approach to treating obesity and type 2 diabetes.
HMC’s Qatar Metabolic Institute receives award for global leadership in tackling obesity at 80th UN General Assembly
September 28, 2025 / Qatar Metabolic Institute / global obesity leadership / WHO UN health award / integrated obesity care / metabolic disease innovation
Qatar’s Metabolic Institute at Hamad Medical Corporation received the 2025 WHO-UN award for global leadership in obesity prevention and care, recognizing its integrated, patient-centered model combining clinical services, research, training, and policy to combat metabolic diseases worldwide.
Faeth Therapeutics Announces Late-Breaking Presentation of Positive Phase 2 Data in Ovarian Cancer at ESMO 2025
September 24, 2025 / ovarian cancer therapy / tumor metabolism targeting / PI3K AKT mTOR / precision oncology nutrition / Faeth Therapeutics ESMO
Faeth Therapeutics’ Phase 2 DICE trial in ovarian cancer showed positive results, combining PI3K/AKT/mTOR inhibitors with precision nutrition. Presented at ESMO 2025, the approach targets tumor metabolism and offers promise for obesity-linked cancers.
How Much Liver Fat Is Too Much? What Parents Need to Know About Childhood Obesity
September 29, 2025 / childhood obesity risks / liver fat in children / pediatric metabolic health / fatty liver disease / obesity-related diabetes
Israeli researchers found that liver fat, not bodyweight, better predicts metabolic complications in children with obesity. Higher liver fat was linked to increased risk of type 2 diabetes, hypertension, and liver disease, highlighting the need for early liver health screening.